MarginsXMarginsX
Home › Markets › Health Care › AKTX

Akari Therapeutics plc ADS (AKTX)

AKTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.51
-4.26% on the day
Market cap
$15.1M
Nano cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerAKTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited Kingdom
IPO yearNot reported by the screener
SEC CIK0001541157
SEC industry codePharmaceutical Preparations
Incorporated inUnited Kingdom

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
5.4 months
$5.7M cash at September 30, 2026
Share count, 1 year
+160.3%
2025-11-13 to 2026-11-12
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern for at least a one-year period following the issuance of these condensed consolidated financial statements."
10-Q 2026-11-12
Cash and burn$5.7M cash; operating cash flow -$3.2M a quarter.Report 2026-09-30
Shares outstanding2,326,149 (2026-11-12); 893,493 a year earlier.Cover page 2026-11-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-17
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2025-11-26
AuditorBDO USA, P.C., New York, New York, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 months1 NT noticeNT 10-Q 2026-05-18
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$4.8M-$4.2M$5.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$4.8M-$3.1M$7.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$14.5M-$2.5M$2.8M$49KNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$5.3M-$3.0M$5.2M$81KNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$6.4M-$2.1M$2.5M$198KNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$1.9M-$3.3M$2.7M$179KNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$3.7M-$2.1M$2.6M$228KNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$3.8M-$2.1M$0$659KNeeds four quarters10-K 2026-03-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-07-02
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-10-01

Source: SEC EDGAR submissions feed, 747 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.7%
1 month-13.9%
3 months-2.9%
Year to date-41.2%
1 year-67.3%
From 52-week high-69.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BOLTBolt Biotherapeutics Inc.$5.80-4.61%$15.1M
CNTXContext Therapeutics Inc.$0.1659-8.24%$15.2M
PBMPsyence Biomedical Ltd. Common Shares$2.83-11.56%$15.0M
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
NCELNewcelX Ltd.$2.75+5.36%$15.9M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier